"Pharmaceutical Speed Reading Society" Aibo Medical Branch Board listed the Drug Administration issued such drugstores need to self-examination.

July 29, 2020 / Pharmaceutical Information List: Aibo Medical Research Board opened up more than 400% on the first day; Topaz Bio and Hansen Pharmaceuticals signed a $68 million cooperation agreement on new leukemia drugs; AstraZeneca Dagli net reached all 3 clinical end points; Fuhong Hanyu Qutoju mono resistance was approved by the European Union to list; Daily fresh medicine news, quick reading with you to pay attention to! Part 1 Policy Brief July 28 98 new confirmed local cases July 28 0-24 hours, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang Production and Construction Corps reported 101 new confirmed cases, of which 3 cases imported from abroad (Guangdong 2 cases, Shanghai 1 case), 98 local cases (89 cases in Xinjiang, 8 cases in Liaoning, 1 case in Beijing);
(National Health And Health Commission) a local drug regulatory bureau issued a text such pharmacies all self-examination 28, Anhui Provincial Drug Administration issued "on the implementation of the main responsibility of special drug operating enterprises to carry out self-examination notice (2020) No. 19."
Requires special drug operating enterprises to conduct a self-examination before June 30 and December 31 of each year in accordance with the List of Self-Inspection Reports on the Implementation of The Main Responsibility of Special Drug Operating Enterprises, which will examine personnel and training, safety management, warehousing management, operation management, mailing and transportation management.
(Anhui Provincial Drug Administration) Part 2 production after observation of the Sanxiang Biotech IPO registration was approved on the 28th, the CSRC issued 4 enterprises, including medical and health enterprises Sanxiang Bio.
sanxiang bio prospectus shows that the IPO, issued no more than 40 million shares, accounting for not less than 10% of the total share capital after the issue, raising 557 million yuan.
(Sina Pharmaceutical News) Aibo Medical Research Board listing opened up more than 400% Aibo Medical to the Shanghai Stock Exchange Science and Technology Board listing, the stock code "688050", the issue price of 33.55 yuan / share.
the first day of trading, Ebo Healthcare opened at 188.88 yuan per share, up 469.30 percent.
will be used for projects such as "Ophthalmology lenses and ancillary products to expand production capacity and automation".
(E-European Health Official) Tiandi Bio appointed Mr. Zhu Yifei as Chief Commercial Officer Tiandi Bio announced the appointment of Mr. Zhu Yifei as Chief Commercial Officer, reporting directly to Dr. Yan Jing-wu, Founder, Honorary Chairman and Director of Tiandi Bio.
, Mr. Zhu Yifei will be fully responsible for the company's commercial layout, the development of commercialization strategy and leadership of relevant teams, for the upcoming product launch to make full preparations.
appointment will enter into force on 10 August 2020.
( U.S. News Agency) Tudor Bio and Hansen Pharmaceuticals signed a $68 million cooperation agreement on new leukemia drugs on the 28th, Tudor Bio and Hansen Pharmaceuticals announced that the two sides signed a product cooperation and licensing agreement.
Pharmaceuticals will receive a development and commercialization interest in Trna-000632, which is used to develop chronic myeloid leukemia-related adaptations, in Greater China.
will receive a down payment of not more than $68 million, research and development, registration, sales milestone payments, and a future product-based sales increase.
(Immediate Drug News) Part 3 Drug News AstraZeneff reached all Phase 3 clinical endpoints AstraZeneff announced that its SGLT2 inhibitor Dagli net reached all major and secondary endpoints in Phase 3 clinical trials for patients with chronic kidney disease (CKD).
results of clinical trials showed that in adult patients with CKD, Dagli net had statistically significant and clinically significant improvements in compound endpoints.
and BioNTech have announced the launch of a global Phase 2/3 clinical study to assess the safety and effectiveness of their new mRNA-based coronary candidate vaccine, BNT162b2, to prevent COVID-19.
clinical trial is expected to recruit 30,000 volunteers.
(Drug Mingkangde) AbbVie JAK Inhibitor Phase 3 clinical trial significantly reduced adeocation dermatitis symptoms AbbVie announced that its JAK inhibitor Rinvoq in association with external corticosteroids, in the treatment of anaesthetic dermatitis in the key Phase 3 clinical trial AD Up, reached a common primary endpoint and all secondary endpoints, this is Rinvoq in the treatment of adythmetic dermatitis in the third critical Phase 3 study results.
on July 28th, Nabriva announced that the European Commission had officially approved its innovative antibiotic Xenleta for adult patients with community-acquired pneumonia (CAP).
new antibiotic approved in Europe in nearly 20 years, providing CAP patients with an important treatment option, according to Nabriva.
(Sina Pharmaceutical News) Fuhong Hanyu Quto zhur resistant to the European Union approved the listing of Fuhong Hanzhu announced that its independent research and development of biosynchent drug quentojuma anti-HLX02 was approved in the European Union for the treatment of HER2-positive early stage breast cancer, HER2-positive metastatic breast cancer, as well as untreated HER2-positive metastatic gastric cancer or gastric/esophageal junction adenocarcinoma.
(Fuhong Hanyu Announcement) Baiotai Adamu anti-injection new adaptive fluid was approved BaiOtai issued a notice that the company recently received the Approval Notice of drug supplementation application for Adamu monoanti injection (commodity name: Glili ®), the new drug was approved for new adaptive disease: Crohn's disease.
(Bai Otai Announcement) Jia and BioPD-1 monoanti-listing applications to be included in the priority review CDE website show that Jia and Bio's PD-1 mono-anti-Jeno anti-injection application was included in the proposed priority review list on 28 July on the grounds of "conditional approval".
applied for the listing of Gianno-monotherapy for the treatment of peri-T-cell lymphoma.
(CDE) Goliath's second class 1 hepatitis C new drug Lavidave was approved in recent days, Goliath Pharmaceuticals Class 1 new drug Lavidave tablets listed in the state of the NMPA changed to "in approval", which means that after Danoreve, The second new hepatitis C drug is about to be approved.
(CPhI Pharmaceuticals Online) cornerstone pharmaceutical company apothyni listing application was given priority review 28, CDE will be the cornerstone of the pharmaceutical company's apothyni tablet listing application formally included in the priority review approval process.
is a KIT/PDGFRA inhibitor developed by Blueprint Medicines to treat advancedIST adult patients with PDGFRA exon 18 mutations.
(Pharmaceutical Rubik's Cube) the first domestic CD38/CD3 double anti-declaration clinical 28, Youzhiyou biological submission of injection recombinant anti-CD38 and CD3 dual-specific antibody clinical application was accepted by CDE, this is the first declared clinical domestic CD38/CD3 double anti.
CD38 is a widely expressed trans-membrane glycoprotein, clinically proven to be the therapeutic target of multiple myeloma.
(Pharmaceutical Rubik's Cube) the first domestic recombinant shingles vaccine approved for clinical trials recently, Shanghai Yiddong Bio and Jiangsu Zhonghui Yuantong jointly declared the nine-price recombinant human papillomavirus vaccine and recombinant shingles vaccine approved clinically, the latter is the first approved clinical domestic recombinant shingles vaccine.
(Pharmaceutical Rubik's Cube) Moderna's new crown vaccine is set to sell for $25-$30 per dose, far more than other companies have quoted, according to foreign media reports, Moderna's proposed company in the study of the new crown vaccine in the United States for $25-30 per dose.
the vaccine will be given in two doses, which means it will cost at least $50 per session.
addition, GMA intends to limit the pricing range for possible new crown vaccines to $40.
(Sina Pharmaceutical News)